Last edition
News about "Pharma.AI platform "
The collaboration between Insilico Medicine and Bora Pharmaceuticals is valued at over USD 2.5 billion if fully implemented and aims to accelerate the discovery, development and commercialisation of next-generation therapies while expanding AI adoption across the pharmaceutical value chain.
Pharma.AI Platform | 16/07/2026 | By News Bureau | 113
Insilico Medicine and SK Biopharmaceuticals have entered an Artificial Intelligence (AI)-powered drug discovery collaboration worth up to USD 2.5 billion to develop innovative therapies for neuroimmune disorders.
Pharma.AI Platform | 23/06/2026 | By News Bureau | 447
Insilico Medicine and Qilu Pharmaceutical Sign USD 120 Million Cardiometabolic Drug Deal
According to the agreement, Insilico Medicine will utilise its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.
Pharma.AI Platform | 28/01/2026 | By News Bureau | 175
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy